News

Quantum computing promises to revolutionize the way we process information by leveraging the principles of quantum mechanics. It will offer unprecedented computational power, enabling solutions to complex problems that are currently unsolvable by classical computers. This breakthrough technology has the potential to transform industries such as cryptography, drug discovery, and artificial intelligence. IonQ Inc (IONQ), FormFactor (FORM), and IBM (IBM) are among the stocks offering exposure to th

(Bloomberg) -- France’s banking stocks slid as a potential government collapse and deepening political crisis unsettled investors.Most Read from BloombergIn Traffic-Weary Toronto, a Battle Breaks Out Over Bike LanesIn Italy’s Motor City, Car-Free Options Are GrowingNew York City’s ‘Living Breakwaters’ Brace for Stormier SeasIn Kansas City, a First-Ever Stadium Designed for Women’s Sports Takes the FieldBNP Paribas SA — the country’s largest lender by market capitalization — fell as much as 3% wh

On Wednesday, the European Commission approved BeiGene Ltd’s (NASDAQ:BGNE) Tevimbra (tislelizumab) in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma (ESCC) and gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. In ESCC, the expanded indication is for Tevimbra in combination with platinum-based chemotherapy for the first-line treatment of adult patients with unresectable, locally advanced or metastatic cancer whose tumors express PD-L1 w

(Bloomberg) -- Trafigura Group has ordered thousands of tons of zinc out of London Metal Exchange warehouses, fueling a rally in prices, according to people familiar with the matter. Most Read from BloombergIn Traffic-Weary Toronto, a Battle Breaks Out Over Bike LanesIn Italy’s Motor City, Car-Free Options Are GrowingNew York City’s ‘Living Breakwaters’ Brace for Stormier SeasIn Kansas City, a First-Ever Stadium Designed for Women’s Sports Takes the FieldOrders to withdraw zinc from warehouses o

Shares of Dell Technologies (DELL) plunged intraday Wednesday after the computer manufacturer report

The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava last year.

Workday gave weaker-than-anticipated guidance for fiscal 2025 subscription services revenue, sending shares tumbling.